Drug Database

Anesthetic agents, paralytics, opioids, pressors, locals, reversals, and antiemetics — with doses, kinetics, contraindications, and pearls.

27 of 27 drugs
Induction

Propofol

Diprivan
GABA-A receptor agonist; potentiates chloride conductance.
Onset
~30 seconds
Duration
5–10 min (single bolus)
Induction

Etomidate

Amidate
GABA-A modulator with minimal cardiovascular effects.
Onset
30–60 seconds
Duration
5–10 min
Induction

Ketamine

Ketalar
Non-competitive NMDA receptor antagonist; produces dissociative anesthesia.
Onset
30–60 sec IV; 3–5 min IM
Duration
10–20 min (IV)
Benzodiazepine

Midazolam

Versed
GABA-A potentiation via benzodiazepine binding site.
Onset
1–3 min IV; 15 min PO
Duration
30–60 min
Induction

Dexmedetomidine

Precedex
Highly selective α2-adrenoceptor agonist — sedation, analgesia, sympatholysis.
Onset
5–10 min
Duration
60–120 min after infusion stop
Neuromuscular Blocker

Succinylcholine

Anectine, Quelicin
ACh receptor agonist → sustained depolarization → flaccid paralysis.
Onset
30–60 sec
Duration
5–10 min
Neuromuscular Blocker

Rocuronium

Zemuron
Competitive ACh receptor antagonist at neuromuscular junction.
Onset
60–90 sec (RSI dose) / 2–3 min (standard)
Duration
30–60 min (longer with high dose)
Neuromuscular Blocker

Vecuronium

Norcuron
Competitive nicotinic ACh receptor antagonist.
Onset
3–5 min
Duration
25–40 min
Neuromuscular Blocker

Cisatracurium

Nimbex
Competitive nicotinic ACh antagonist.
Onset
2–3 min
Duration
30–60 min
Opioid

Fentanyl

Sublimaze
μ-opioid receptor agonist; 75–125× more potent than morphine.
Onset
1–2 min
Duration
30–60 min (single dose); context-sensitive half-time grows with infusion.
Opioid

Remifentanil

Ultiva
μ-opioid agonist; metabolized by non-specific plasma esterases.
Onset
1–2 min
Duration
3–10 min regardless of infusion duration
Opioid

Sufentanil

Sufenta
μ-opioid receptor agonist; 5–10× more potent than fentanyl.
Onset
1–3 min
Duration
30–60 min
Opioid

Morphine

μ-opioid receptor agonist.
Onset
5–10 min IV
Duration
3–4 h IV; up to 24 h intrathecal
Opioid

Hydromorphone

Dilaudid
μ-opioid receptor agonist; ~5–7× more potent than morphine.
Onset
5–10 min IV
Duration
3–4 h
Vasopressor / Inotrope

Phenylephrine

Selective α1 vasoconstriction; reflex bradycardia possible.
Onset
<1 min
Duration
5–20 min (bolus)
Vasopressor / Inotrope

Ephedrine

Releases endogenous NE; direct α and β effects.
Onset
1 min
Duration
10–60 min
Vasopressor / Inotrope

Norepinephrine

Levophed
α1 vasoconstriction with mild β1 inotropy.
Onset
<1 min
Duration
1–2 min
Vasopressor / Inotrope

Epinephrine

Low dose: β-predominant (inotropy, vasodilation). High dose: α-predominant.
Onset
<1 min IV
Duration
5–10 min
Vasopressor / Inotrope

Vasopressin

V1 receptor agonism → vasoconstriction independent of adrenergic system.
Onset
1–3 min
Duration
10–20 min
Local Anesthetic

Lidocaine

Xylocaine
Blocks voltage-gated Na+ channels.
Onset
Rapid (1–5 min infiltration)
Duration
1–2 h (4 h with epi)
Local Anesthetic

Bupivacaine

Marcaine, Sensorcaine
Blocks voltage-gated Na+ channels with high cardiac affinity.
Onset
5–10 min (infiltration); 5–8 min (epidural)
Duration
4–8 h
Local Anesthetic

Ropivacaine

Naropin
Na+ channel blockade; preferential sensory > motor block.
Onset
10–20 min
Duration
3–6 h
Reversal Agent

Sugammadex

Bridion
Encapsulates rocuronium/vecuronium 1:1, removing them from NMJ.
Onset
1–3 min
Duration
Pharmacologic effect ~24 h
Reversal Agent

Neostigmine

Inhibits AChE → ↑ACh at NMJ; outcompetes non-depolarizers.
Onset
5–10 min
Duration
60 min
Reversal Agent

Naloxone

Narcan
Competitive μ-opioid receptor antagonist.
Onset
1–2 min
Duration
30–60 min (less than most opioids — re-narcotization risk)
Antiemetic

Ondansetron

Zofran
Blocks 5-HT3 receptors in CTZ and vagal afferents.
Onset
5–15 min
Duration
4–8 h
Antiemetic

Dexamethasone

Decadron
Unclear antiemetic mechanism; anti-inflammatory.
Onset
Hours (analgesic effect ~1 h)
Duration
24+ h